Developing tTA transgenic rats for inducible and reversible gene expression

International Journal of Biological Sciences

Volumn 5, Issue 2, 2009, Pages 171-181

  Zhou, Hongxia ^a   Huang, Cao ^a   Yang, Min ^a   Landel, Carlisle P ^b   Xia, Pedro Yuxing ^c   Liu, Yong Jian ^d   Xia, Xu Gang ^a,e  

^a Anatomy and Cell Biology ^*  (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Lower Merion High School   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Doxycycline; Leucine rich repeat kinase 2; LRRK2; Rats; Tetracycline controlled transactivator; Transgenic; tTA

Indexed keywords

DOXORUBICIN; TRANSACTIVATOR PROTEIN; ANTIINFECTIVE AGENT; DOXYCYCLINE; MESSENGER RNA; TETRACYCLINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC MODEL; LOW DRUG DOSE; NONHUMAN; PROMOTER REGION; RAT; REPORTER GENE; TRANSGENIC RAT; ANIMAL; BIOTINYLATION; DOSE RESPONSE; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; NEWBORN; PREGNANCY; SUCKLING; TRANSGENE;

RATTUS;

ANIMALS; ANIMALS, NEWBORN; ANIMALS, SUCKLING; ANTI-BACTERIAL AGENTS; BIOTINYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION; GENES, REPORTER; IMMUNOHISTOCHEMISTRY; PREGNANCY; PROMOTER REGIONS, GENETIC; RATS; RATS, TRANSGENIC; RNA, MESSENGER; TETRACYCLINE; TRANS-ACTIVATORS; TRANSGENES;

EID: 61549107548     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.5.171     Document Type: Article

References (52)

1. Tesson L, Cozzi J, et al. Transgenic modifications of the rat genome. Transgenic Res 2005;14(5):531-46.
2. Filipiak WE, Saunders TL. Advances in transgenic rat pro-duc-tion. Transgenic Res 2006;15(6):673-86.
3. Aiba A., Nakao H. Conditional mutant mice using tet-racy-cline-controlled gene expression system in the brain. Neurosci Res 2007;58(2):113-7.
4. Fisch SG. Animal models and human neuropsychiatric disor-ders. Behav Genet 2007;37(1):1-10.
5. Gaveriaux-Ruff C., Kieffer LB. Conditional gene targeting in the mouse nervous system: Insights into brain function and dis-eases. Pharmacol Ther 2007;113(3):619-34.
6. Lull EM, Freeman MW, Vrana EK, Mash CD. Correlating hu-man and animal studies of cocaine abuse and gene expression. Ann N Y Acad Sci 2008;1141:58-75.
7. Bouwknecht AJ, Paylor R. Pitfalls in the interpretation of genetic and pharmacological effects on anxiety-like behaviour in rodents. Behav Pharmacol 2008;19(5-6):385-402.
8. Cao Q., Xu, et al. Functional recovery in traumatic spinal cord injury after transplantation of multineurotrophin-expressing glial-restricted precursor cells. J Neurosci 2005;25(30):6947-57.
9. Zhang PY, Shields, et al. Use of magnetic stimulation to elicit motor evoked potentials, somatosensory evoked potentials, and H-reflexes in non-sedated rodents. J Neurosci Methods 2007;165(1):9-17.
10. Niwa H. Molecular mechanism to maintain stem cell renewal of ES cells. Cell Struct Funct 2001;26(3):137-48.
11. Buehr M., Meek, et al. Capture of authentic embryonic stem cells from rat blastocysts. Cell 2008;135(7):1287-98.
12. Li P., Tong, et al. Germline competent embryonic stem cells derived from rat blastocysts. Cell 2008;135(7):1299-310.
13. Cheng HJ, She, et al. Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2008;294(1):G39-49.
14. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990;344(6266):541-4.
15. Herrera VL, Makrides SC, Xie HX, Adari H, Krauss RM, Ryan US, Ruiz-Opazo N. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cho-les-teryl ester transfer protein. Nat Med 1999;5(12):1383-9.
16. von Horsten S, Schmitt I, Nguyen HP, et al. Transgenic rat model of Huntington's disease. Hum Mol Genet 2003;12(6):617-24.
17. Mordes JP, Bortell R, Blankenhorn EP, Rossini AA, Greiner DL. Rat models of type 1 diabetes: genetics, environment, and autoimmunity. Ilar J 2004;45(3):278-91.
18. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 1999;5(6):601-4.
19. Chaillous L., Lefevre, et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 2000;356(9229):545-9.
20. Atkinson AM, Maclaren KN, Luchetta R. Insulitis and dia-betes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990;39(8):933-7.
21. Mullins JL, Mullins JJ. Insights from the rat genome se-quence. Genome Biol 2004;5(5):221.
22. Gibbs RA, Weinstock GM, Metzker ML, et al. Genome sequence of the Brown Norway rat yields insights into mammalian evo-lution. Nature 2004;428(6982):493-521.
23. Canzian F. Phylogenetics of the laboratory rat Rattus norvegicus. Genome Res 1997;7(3):262-7.
24. Kuan YC, Yang, et al. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain de-velopment. Neuron 1999;22(4):667-76.
25. Fon AE, Pothos, et al. Vesicular transport regulates monoam-ine storage and release but is not essential for amphetamine ac-tion. Neuron 1997;19(6):1271-83.
26. Hong KH, Chong, et al. Inducible and reversible Clock gene expression in brain using the tTA system for the study of cir-cadian behavior. PLoS Genet 2007;3(2):e33.
27. Zhu Z, Zheng T, Lee CG, Homer RJ, Elias JA. Tet-racy-cline-controlled transcriptional regulation systems: advances and application in transgenic animal modeling. Semin Cell Dev Biol 2002;13(2):121-8.
28. Stark KL, Gross C, et al. A novel conditional knockout strategy applied to serotonin receptors. Handb Exp Pharmacol 2007; 178:347-63.
29. Braudeau C, Bouchet D, Toquet C, et al. Generation of heme oxygenase-1-transgenic rats. Exp Biol Med (Maywood) 2003;228(5):466-71.
30. Tesson L, Cozzi J, Menoret S, Remy S, Usal C, Fraichard A, Anegon I. Transgenic modifications of the rat genome. Trans-genic Res 2005;14(5):531-46.
31. van den Brandt J, Wang D, Kwon SH, Heinkelein M, Reichardt HM. Lentivirally generated eGFP-transgenic rats allow efficient cell tracking in vivo. Genesis 2004;39(2):94-9.
32. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes de-livered by lentiviral vectors. Science 2002;295(5556):868-72.
33. Heng YM, Detloff JP, Albin LR. Rodent genetic models of Huntington disease. Neurobiol Dis 2008;32(1):1-9.
34. Cozzi J., Fraichard A., Thiam K. Use of genetically modified rat models for translational medicine. Drug Discov Today 2008;13(11-12):488-94.
35. Niwa H., Yamamura K., Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991;108(2):193-9.
36. Novak A., Guo, et al. Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis 2000;28(3-4):147-55.
37. Zhou H, Falkenburger BH, Schulz JB, Tieu K, Xu Z, Xia XG. Silencing of the Pink1 Gene Expression by Conditional RNAi Does Not Induce Dopaminergic Neuron Death in Mice. Int J Biol Sci 2007;3(4):242-50.
38. Biskup S., Moore, et al. Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci 2007;8:102.
39. Sanbe A., Gulick, et al. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res 2003;92(6):609-16.
40. Barton DM, Dunlop, et al. Modified GFAP promoter auto-regulates tet-activator expression for increased trans-acti-vation and reduced tTA-associated toxicity. Brain Res Mol Brain Res 2002;101(1-2):71-81.
41. Tesson L., Charreau, et al. Endothelial expression of Fas ligand in transgenic rats under the temporal control of a tet-racy-cline-inducible system. Transplant Proc 1999;31(3):1533-4.
42. Kubo J., Yamanouchi K., Naito K., Tojo H. Expression of the gene of interest fused to the EGFP-expressing gene in trans-genic mice derived from selected transgenic embryos. J Exp Zool 2002;293(7):712-8.
43. Vintersten K., Monetti, et al. Mouse in red: red fluorescent protein expression in mouse ES cells, embryos, and adult ani-mals. Genesis 2004;40(4):241-6.
44. Morimoto M., Kopan R. rtTA toxicity limits the usefulness of the SP-C-rtTA transgenic mouse. Dev Biol 2009;325(1):171-8.
45. Klein RL, King MA, Hamby ME, Meyer EM. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum Gene Ther 2002;13(5):605-12.
46. Maingay M., Romero-Ramos M., Kirik D. Viral vector medi-ated overexpression of human alpha-synuclein in the ni-grostriatal dopaminergic neurons: a new model for Parkinson's disease. CNS Spectr 2005;10(3):235-44.
47. Hashimoto M., Rockenstein E., Masliah E. Transgenic models of alpha-synuclein pathology: past, present, and future. Ann N Y Acad Sci 2003;991:171-88.
48. Sage J., Miller, et al. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003;424(6945):223-8.
49. Jaeschke A., Karasarides, et al. JNK2 is a positive regulator of the cJun transcription factor. Mol Cell 2006;23(6):899-911.
50. Sabapathy K, Hochedlinger K, Nam SY, Bauer A, Karin M, Wagner EF. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell 2004;15(5):713-25.
51. Xia GX, Zhou, et al. Pol II-expressed shRNA knocks down Sod2 gene expression and causes phenotypes of the gene knockout in mice. PLoS Genet 2006;2(1):27.
52. Dickins AR, McJunkin, et al. Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet 2007;39(7):914-21.